Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients
Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Amarnath Sharma, Jennifer Smit(Janssen (United States)), Brandi Hilder(Sheba Medical Center), Shun Xin Wang Lin(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Brett Hanna(Janssen (United States)), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Jeffrey R. Infante(Cancer Research Center), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Shoba Shetty(Janssen (United States)), Yusri Elsayed(Janssen (United States)), Homer Adams(Janssen (United States)), Yu‐Nien Sun(Janssen (United States)), Kodandaram Pillarisetti(Johnson & Johnson (United States))
Cited by 2
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k